William Blair Lowers Earnings Estimates for Cooper Companies

The Cooper Companies, Inc. (NASDAQ:COO - Free Report) - William Blair decreased their Q1 2025 EPS estimates for Cooper Companies in a report issued on Monday, December 9th. William Blair analyst M. Andrew now anticipates that the medical device company will post earnings per share of $0.92 for the quarter, down from their prior forecast of $0.95. The consensus estimate for Cooper Companies' current full-year earnings is $3.98 per share. William Blair also issued estimates for Cooper Companies' Q2 2025 earnings at $0.94 EPS, Q3 2025 earnings at $1.04 EPS and FY2025 earnings at $3.98 EPS.

Other analysts have also recently issued reports about the stock. StockNews.com cut shares of Cooper Companies from a "buy" rating to a "hold" rating in a research report on Wednesday. Stifel Nicolaus reiterated a "buy" rating and issued a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Wells Fargo & Company raised their target price on Cooper Companies from $115.00 to $118.00 and gave the company an "overweight" rating in a report on Friday, December 6th. Morgan Stanley decreased their price target on Cooper Companies from $104.00 to $102.00 and set an "equal weight" rating for the company in a report on Friday, December 6th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Cooper Companies in a research note on Friday, December 6th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $117.00.

Cooper Companies Trading Down 2.2 %

Shares of Cooper Companies stock traded down $2.16 during trading hours on Thursday, hitting $97.12. The company's stock had a trading volume of 1,122,119 shares, compared to its average volume of 1,158,266. The business has a fifty day moving average of $103.92 and a 200 day moving average of $98.88. Cooper Companies has a 1-year low of $84.76 and a 1-year high of $112.38. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $19.34 billion, a PE ratio of 50.91, a P/E/G ratio of 2.17 and a beta of 0.97.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.04. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.03 billion. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company's revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.87 EPS.

Institutional Investors Weigh In On Cooper Companies

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp boosted its holdings in shares of Cooper Companies by 1.2% during the third quarter. State Street Corp now owns 8,590,689 shares of the medical device company's stock valued at $947,897,000 after acquiring an additional 104,521 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its position in Cooper Companies by 3.0% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company's stock valued at $682,738,000 after purchasing an additional 231,155 shares during the last quarter. Geode Capital Management LLC boosted its stake in Cooper Companies by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 4,796,556 shares of the medical device company's stock valued at $527,476,000 after purchasing an additional 48,559 shares during the period. Victory Capital Management Inc. grew its position in Cooper Companies by 23.0% in the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company's stock worth $435,856,000 after purchasing an additional 737,726 shares during the last quarter. Finally, Impax Asset Management Group plc increased its stake in shares of Cooper Companies by 31.0% in the second quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company's stock valued at $205,511,000 after purchasing an additional 558,886 shares during the period. Institutional investors and hedge funds own 24.39% of the company's stock.

Insider Buying and Selling

In other news, CEO Albert G. White III sold 114,992 shares of the firm's stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the transaction, the chief executive officer now directly owns 165,273 shares in the company, valued at approximately $18,267,624.69. This trade represents a 41.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 2.00% of the company's stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.